In the ever-evolving landscape of medical science, few fields have witnessed as profound a transformation in recent decades as cell and gene therapy (CGT). These groundbreaking modalities, which include the transplantation of living cells and the genetic modification of cellular functions, are not merely concepts of the future—they are actively reshaping clinical practices worldwide. Researchers have long regarded CGT as a beacon of hope for treating diseases that have historically eluded effective intervention. Yet, despite the undeniable promise, the field’s advancement has been marked by varying degrees of progress across different therapeutic types and geographic regions.
A comprehensive inquiry into this phenomenon was recently undertaken by a team at Kyoto University in collaboration with Arthur D. Little Japan. Harnessing the power of bibliometric analysis, the group meticulously examined over 160,000 scholarly articles published between 1989 and 2023, sourced from PubMed and OpenAlex databases. This extensive dataset provided an unprecedented vantage point to track the evolution of CGT research trends and to assess the contributions from major global players. Static numbers alone, however, were insufficient to fully characterize the dynamics of this field, which prompted a closer qualitative evaluation alongside quantitative metrics.
The findings brought to light a dual narrative of progress and stagnation. Hematopoietic stem cell transplantation (HSCT), including the prevalent bone marrow transplantation technique, along with ex vivo gene therapies—where genetic modifications occur outside the patient’s body before reinfusion—have shown consistent and robust growth. These areas have steadily moved closer to widespread clinical application, supported by a growing corpus of scientific literature and translational breakthroughs. In stark contrast, mesenchymal stem cell therapy and in vivo gene therapy, which involve direct administration to combat inflammation and facilitate genetic alteration inside the body respectively, have struggled to achieve comparable momentum in clinical adoption.
An intriguing geographic disparity emerged when the researchers delved into regional publication trends. Japan, despite its long-standing expertise in regenerative medicine, contributes a substantial volume of research papers on cell therapy. However, these works often lack the decisive qualitative impact necessary to drive global standards or influence clinical guidelines significantly. Conversely, the United States and China dominate the field—not only by the sheer number of publications but also through the production of high-impact studies that frequently serve as reference points for future innovations. Importantly, many of these influential works bear the hallmark of international collaboration, underscoring the synergistic value of cross-border research partnerships.
The notion that collaboration begets impact was crystallized by team leader Sumimasa Nagai, who highlighted the robust ties binding Europe and the United States as well as notable academic networks within Europe itself. These collaborative networks function as innovation ecosystems, enabling the fusion of diverse expertise, shared resources, and novel investigative approaches that collectively fuel scientific breakthroughs. Nonetheless, geopolitical shifts and fluctuations in research funding—particularly in the United States—pose uncertain challenges to these well-established collaborative frameworks, potentially reshaping the future landscape of CGT innovation.
From a methodological perspective, the Kyoto team’s bibliometric approach represents a critical advancement in understanding the trajectory of CGT. By integrating data analytics with domain-specific expertise, the study offers a nuanced map of progress that moves beyond traditional literature reviews. This analytical lens facilitates the identification of not only prolific research clusters but also emerging subfields and underexplored therapeutic avenues. Such insights can guide strategic decisions by policymakers, funding agencies, and academic institutions aiming to optimize the allocation of research resources and streamline the pathway from bench to bedside.
Beyond the realm of pure publication metrics, the team acknowledges the necessity of incorporating supplementary dimensions such as patent landscapes, regulatory frameworks, and financial investment trends. These factors critically influence the translation of scientific discoveries into viable therapies accessible to patients. Therefore, future research efforts are set to expand the analytical framework, adapting multi-layered data integration to holistically capture the complete innovation lifecycle in regenerative medicine, including CGT.
Japan’s unique position in this global mosaic is pivotal. With its strong foundational capabilities in cell biology and regenerative science, the country is poised to move beyond academic production and into impactful societal implementation. The current study lays the groundwork for this strategic transition, aiming to consolidate Japan’s strengths and foster synergistic collaborations that amplify both scientific and clinical outcomes. Realizing these ambitions will require concerted efforts to elevate research quality, enhance international partnerships, and navigate complex regulatory pathways.
While progress in CGT heralds transformative potential for patients suffering from conditions once deemed intractable, the uneven advancements evidenced by this bibliometric analysis serve as a clarion call for sustained, coordinated action. Advancing cell and gene therapy from experimental phases into mainstream medicine hinges on bridging divides—whether they be technological, geographic, or institutional. The lessons gleaned from this extensive research underscore that innovation thrives where diverse minds converge and where infrastructure and policy environments support rather than hinder scientific exploration.
As the field marches forward, the integration of new technologies such as CRISPR-based genome editing, advanced cell manufacturing techniques, and artificial intelligence-driven analytics promises to accelerate discovery and application. These emerging tools dovetail perfectly with the existing momentum in ex vivo gene therapies and hematopoietic transplantation, potentially expanding therapeutic frontiers and unraveling new disease mechanisms. However, addressing the stagnation in other CGT domains will require nuanced approaches tailored to biological, clinical, and regulatory complexities unique to those therapies.
In summation, this landmark bibliometric study paints a detailed picture of the past 35 years of CGT research, illuminating patterns of growth, identifying regional strengths and weaknesses, and advocating for enhanced international collaboration. The outcomes not only chronicle scientific progress but also chart a strategic course for future endeavors, emphasizing that the intersection of robust data analytics and interdisciplinary cooperation is indispensable to turning cellular and genetic therapies into universal standards of care. With the foundations firmly established, the coming decades hold promise for CGT to fulfill its transformative promise in medicine.
Subject of Research: Cells
Article Title: Advancement in Cell and Gene Therapy Research: a 35-Year Bibliometric Perspective
News Publication Date: 10-Jan-2026
Web References:
http://dx.doi.org/10.1016/j.jcyt.2026.102056
References:
Advancement in Cell and Gene Therapy Research: a 35-Year Bibliometric Perspective. Cytotherapy. 10 January 2026. DOI: 10.1016/j.jcyt.2026.102056
Image Credits:
Yuki Kitahara and Sumimasa Nagai
Keywords:
Gene therapy, Medical treatments, Clinical medicine, Bibliometrics, Impact factors, Scientific collaboration
